Alpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies

Abstract

We have developed a novel real‐time quaking‐induced conversion RT ‐Qu IC ‐based assay to detect alpha‐synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha‐synuclein aggregation in Dementia with Lewy bodies and Parkinson's disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT ‐QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha‐synucleinopathies.

References 20

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.
    Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein · 2015

    No notice
19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 25

• Propagative α-synuclein seeds as serum biomarkers for synucleinopathies · 2023
  Corrected
• Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease · 2022
  No notice
• Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies · 2022
  No notice
• Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies · 2021
  No notice
• High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease · 2021
  Corrected
• RT‐QuIC Detection of Pathological α‐Synuclein in Skin Punches of Patients with Lewy Body Disease · 2021
  No notice
• Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies · 2021
  No notice
• Neuropathology and molecular diagnosis of Synucleinopathies · 2021
  No notice
• Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease · 2021
  No notice
• Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease · 2021
  No notice
• Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease · 2020
  No notice
• Initiation and propagation of α-synuclein aggregation in the nervous system · 2020
  No notice
• Invited Review: The role of prion‐like mechanisms in neurodegenerative diseases · 2020
  No notice
• Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies · 2020
  Corrected
• Prion-Like Mechanisms in Parkinson’s Disease · 2019
  Not checked
• Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy · 2019
  No notice
• Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 · 2019
  No notice
• Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease · 2019
  No notice
• Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease · 2019
  No notice
• Current state of Alzheimer’s fluid biomarkers · 2018
  No notice

and 5 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.